Anavex CEO Terrie Kellmeyer receives 200,000 options

The options vest in three substantially equal annual installments beginning May 4, 2027, and expire November 2, 2036.

Available on EDGAR 11/06/2026 - 08:11 PM EST Accepted by SEC EDGAR 11/06/2026 - 08:11 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Anavex Life Sciences Corp. (AVXL) President and CEO and director Terrie Kellmeyer received a grant of 200,000 stock options on November 3, 2026, with an exercise price of $1.20 per share. The options cover 200,000 shares of common stock and vest in three substantially equal annual installments beginning May 4, 2027. They expire November 2, 2036; the reported resulting position is 200,000 options.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Kellmeyer Terrie

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	200,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 200,000 options (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 200,000 options (Direct)

Footnotes (1)

1. F1. The option was granted pursuant to the terms of the Reporting Person's employment agreement with the Issuer, dated May 4, 2026, and vests in three substantially equal annual installments beginning on May 4, 2027

Key Figures

Stock options granted: 200,000 options Underlying common stock: 200,000 shares Exercise price: $1.20 per share +2 more

5 metrics

Stock options granted 200,000 options Grant dated November 3, 2026

Underlying common stock 200,000 shares Shares covered by the options

Exercise price $1.20 per share Stock options

Resulting option position 200,000 options Reported following the grant

Annual vesting installments 3 installments Substantially equal; beginning May 4, 2027

Key Terms

Stock Option (Right to Buy), exercise price, annual installments, employment agreement

4 terms

Stock Option (Right to Buy) technical

"Stock Option (Right to Buy)"

exercise price financial

"exercise price of $1.20 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual installments technical

"vests in three substantially equal annual installments"

employment agreement technical

"terms of the Reporting Person's employment agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AVXL options did Terrie Kellmeyer receive?

Terrie Kellmeyer received 200,000 stock options on November 3, 2026. The options cover 200,000 shares of common stock and have an exercise price of $1.20 per share.

Was Terrie Kellmeyer's AVXL option grant tied to her employment agreement?

Yes. The 200,000-option award was granted pursuant to the terms of Terrie Kellmeyer's employment agreement with Anavex Life Sciences Corp., dated May 4, 2026. The options vest in three substantially equal annual installments beginning May 4, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kellmeyer Terrie

(Last) (First) (Middle)

630 5TH AVENUE 20TH FLOOR

(Street)

NEW YORK NEW YORK 10111

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.2	11/03/2026		A		200,000		(1)	11/02/2036	Common Stock	200,000	$0	200,000	D

Explanation of Responses:

1. The option was granted pursuant to the terms of the Reporting Person's employment agreement with the Issuer, dated May 4, 2026, and vests in three substantially equal annual installments beginning on May 4, 2027

	/s/Terrie Kellmeyer	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)